PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Atherosclerosis10.1016/j.atherosclerosis.2022.06.6552022355149Approach of therapeutics goals in a group of patients with familial hypercholesterolemia under PCSK9 inhibitors treatmentA.C. Puente, P.I. Olivares, R. Trujillohttps://api.elsevier.com/content/article/PII:S002191502200942X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S002191502200942X?httpAccept=text/plain
Progress in Cardiovascular Diseases10.1016/j.pcad.2016.07.0112016592165-171Nonstatins and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Role in Non‐Familial HypercholesterolemiaJennifer G. Robinsonhttps://api.elsevier.com/content/article/PII:S0033062016300755?httpAccept=text/plain, https://api.elsevier.com/content/article/PII:S0033062016300755?httpAccept=text/xml
Endocrinology and Metabolism10.3803/enm.2021.9642021362279-295Role of PCSK9 Inhibitors in Patients with Familial HypercholesterolemiaBrian Tomlinson, Nivritti Gajanan Patil, Manson Fok, Christopher Wai Kei Lamhttp://e-enm.org/upload/pdf/enm-2021-964.pdf, http://e-enm.org/journal/view.php?doi=10.3803/EnM.2021.964, http://e-enm.org/upload/pdf/enm-2021-964.pdf
Atherosclerosis10.1016/j.atherosclerosis.2020.10.6542020315e209Homozyous familial hypercholesterolemia (HOFH): Pause prior to prescribing pricey PCSK9 inhibitors !S. Iyengar, V. Subash Chandra, L. Sumithrahttps://api.elsevier.com/content/article/PII:S0021915020312363?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0021915020312363?httpAccept=text/plain
Atherosclerosis10.1016/j.atherosclerosis.2017.06.7772017263e239Features of first patients treated with PCSK9 inhibitors in a specific lipid unit and effectiveness on lipid profile in familial hypercholesterolemiaInma González Molero, Gabriel Olveira, Francisco Tinahoneshttps://api.elsevier.com/content/article/PII:S0021915017310262?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0021915017310262?httpAccept=text/plain
Journal of Clinical Lipidology10.1016/j.jacl.2020.03.0072020144542Arterial stiffness improvement after adding on PCSK9 inhibitors in patients with familial hypercholesterolemiaTheodore G. Papaioannou, Krystallenia I. Alexandraki, Dimitrios Tousoulishttps://api.elsevier.com/content/article/PII:S1933287420300696?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1933287420300696?httpAccept=text/plain
The Journal for Nurse Practitioners10.1016/j.nurpra.2016.05.0052016128577-578PCSK9 Inhibitors for Familial HypercholesterolemiaChristy M. Lenahan, Deedra Harringtoonhttps://api.elsevier.com/content/article/PII:S1555415516301787?httpAccept=text/plain, https://api.elsevier.com/content/article/PII:S1555415516301787?httpAccept=text/xml
Atherosclerosis10.1016/j.atherosclerosis.2016.09.0012017256134-145Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitorsMarcello Arcahttps://api.elsevier.com/content/article/PII:S0021915016313156?httpAccept=text/plain, https://api.elsevier.com/content/article/PII:S0021915016313156?httpAccept=text/xml
Atherosclerosis10.1016/j.atherosclerosis.2022.06.8722022355223Effect of PCSK9 inhibitors on cardio-ankle vascular index in familial hypercholesterolemia subjectsA.S. Postadzhiyan, I. Tzvetkov, L. Andreeva, B. Finkov, V. Velchevhttps://api.elsevier.com/content/article/PII:S0021915022011595?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0021915022011595?httpAccept=text/plain
Journal of the American College of Cardiology10.1016/j.jacc.2020.05.0332020762143-145PCSK9 Inhibitors for Homozygous Familial HypercholesterolemiaGilbert R. Thompsonhttps://api.elsevier.com/content/article/PII:S0735109720353444?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0735109720353444?httpAccept=text/plain